LINDSEY FREKING: Open Payments
NPI 1215374665 · CENTEREACH, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$847 in 38 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $305 · 2025 $847
Food & beverage: $847
| Company | Payments | Amount |
|---|---|---|
| ACADIA Pharmaceuticals Inc | 5 | $197 |
| ABBVIE INC. | 10 | $181 |
| Neurocrine BioSciences, Inc. | 4 | $89 |
| E.R. Squibb & Sons, L.L.C. | 4 | $84 |
| Lundbeck LLC | 3 | $67 |
| Otsuka America Pharmaceutical, Inc. | 3 | $45 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $42 |
| Alkermes, Inc. | 2 | $33 |
| Axsome Therapeutics, Inc. | 1 | $29 |
| Vanda Pharmaceuticals Inc. | 1 | $25 |
Products named: NUPLAZID, VRAYLAR, REXULTI, INGREZZA, COBENFY, CAPLYTA, ARISTADA, Auvelity.
Industry payments across NY — which companies pay providers there.
